$EYPT News

Cantor Fitzgerald Assumes EyePoint at Overweight, Announces Price Target of $47

Chardan Capital Maintains Buy on EyePoint, Raises Price Target to $65

Guggenheim Reiterates Buy on EyePoint, Maintains $68 Price Target

EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears

How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets

EyePoint Announces Participation at Upcoming Investor Conferences

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

EyePoint: DURAVYU's Durability Could Drive Significant Upside

EyePoint (EYPT) Q1 2026 Earnings Transcript

RBC Capital Maintains Outperform on EyePoint, Lowers Price Target to $37

EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript

Eyepoint Pharmaceuticals Q1 Earnings Call Highlights

EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates

EyePoint Inc. (NASDAQ:EYPT) Revenue Beats Estimates, Earnings Miss in Q1 2026 Report

Is It Time To Reassess EyePoint (EYPT) After A 120% One Year Share Price Surge

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments